MIRA Pharmaceuticals, Inc. MIRA

MIRA Company Overview

MIRA Pharmaceuticals, Inc. is a U.S.-based preclinical-stage pharmaceutical company focused on the development of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The company operates within the biotechnology and specialty pharmaceutical industries, with research efforts centered on synthetic cannabinoid analogs and ketamine-based compounds intended to address conditions with significant unmet medical needs. Public filings and corporate disclosures indicate that MIRA’s primary value drivers are its intellectual property portfolio, drug-development pipeline, and commercialization potential for proprietary compounds rather than current product sales or operating revenue.

The company’s lead development programs have included Ketamir-2, a ketamine analog being evaluated for potential applications in neuropathic pain and depressive disorders, and cannabinoid-related compounds designed to target anxiety, cognitive impairment, and metabolic dysfunction. MIRA positions itself around the development of orally administered therapies intended to reduce side effects commonly associated with existing treatments while preserving therapeutic efficacy. The company evolved from an early-stage biotech platform into a publicly traded pharmaceutical development company through capital markets financing and expanded research initiatives focused on central nervous system disorders.